Danilon Equidos Sachets

For oral administration. When added to a portion of feed the product will be accepted by most horses. The following should be used as a guide, according to individual response: Horses: For a 480 kg bodyweight horse, the contents of 2 sachets should be administered twice daily (equivalent to 12.5 mg of suxibuzone/kg/day) for 2 days, followed by 1 sachet twice daily (6.25 mg of suxibuzone/kg/day) for 3 days. Thereafter, 1 sachet daily (3.1 mg of suxibuzone/kg/day) or on alternate days, or the minimum dose necessary for a satisfactory clinical response. Ponies: Ponies should receive only half the dose rate recommended for horses. For a 240 kg bodyweight pony, the contents of 1 sachet should be administered daily (equivalent to 6.25 mg of suxibuzone/kg/day) for 2 days, followed by 1/2 sachet daily (3.1 mg of suxibuzone/kg/day) for 3 days or 1 sachet on alternate days. Thereafter, reduce the dose to the minimum dose necessary for a satisfactory clinical response. For administration of less than one sachet, use the measuring scoop provided. One full level scoop contains 5 g granules (equivalent to 1/2 sachet) and up to the green line level contains 2,5 g granules (equivalent to 1/4 sachet). Hay, as part of the diet, may delay the absorption of suxibuzone and so the onset of clinical effect. It is advisable not to feed hay immediately prior to, or with DANILON equidos. See also special precautions for use. If no clinical response is evident after 4-5 days, discontinue treatment and reconsider the diagnosis. Overdose (symptoms, emergency procedures, antidotes): In case of accidental continuous overdose, the following symptoms may be observed: Thirst, depression, anorexia and weight loss Gastrointestinal disorders (irritation, ulcers, diarrhoea and blood in the faeces) Altered blood profiles and haemorrhages Hypoproteinemia with ventral oedema causing hemoconcentration, hypovolemic shock and circulatory collapse. Renal failure and fluid retention. If signs of intolerance appear, discontinue treatment and establish symptomatic therapy. A slow intravenous perfusion of a solution of sodium bicarbonate, which leads to urine alkalinisation, increases the clearance of the product.